Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.
Latest website image capture
Clouds background image

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Footer updates include a new Revision: v3.3.3 and the removal of the HHS Vulnerability Disclosure link, with Revision: v3.3.2 deleted. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T08:37:41.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added, replacing the previous v3.3.1.
    Difference
    0.1%
    Check dated 2025-12-01T17:23:33.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The Publications section wording was clarified to indicate results of the study, and the revision note updated from v3.2.0 to v3.3.1.
    Difference
    0.1%
    Check dated 2025-11-24T14:38:10.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    Notice about government funding lapse and operating status updates has been removed from the page; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:47:55.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    The updates are minor adjustments that do not modify core study details such as eligibility, endpoints, or enrollment. The study’s primary purpose remains unchanged.
    Difference
    0.5%
    Check dated 2025-11-03T01:16:14.000Z thumbnail image
  9. Check
    93 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    2%
    Check dated 2025-10-05T10:12:57.000Z thumbnail image

Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.